Mesenchymal Stromal Cell Derivatives in the Treatment of Chronic Diabetic Foot Ulcers Type 1 and 2
Status:
Unknown status
Trial end date:
2019-01-01
Target enrollment:
Participant gender:
Summary
The goal of this study is to evaluate the safety and efficacy of using mesenchymal stromal
cell derivatives (dac-MSCs) in the treatment of chronic diabetic foot ulcers (type 1 and 2)
in adults. A third of the participants will receive dac-MSCs and Triticum vulgare
(Fitostimoline) in combination, the other third MSCs and Fitostimoline in combination, and
the last third only Fitosimoline. This study will be a randomized, blind, and parallel and
controlled-group trial.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
Universidad Autónoma de Bucaramanga
Collaborators:
Fundación Oftalmológica de Santander Clínica Carlos Ardila Lulle Instituto Colombiano para el Desarrollo de la Ciencia y la Tecnología (COLCIENCIAS)